Characterization of endothelium-derived hyperpolarizing factor in the human forearm microcirculation

Plain-language guide to PMID 11356600 (2001): clinical trial study of Bradykinin, hyperparathyroidism.

Key Facts

PMID: 11356600
Journal: American journal of physiology. Heart and circulatory physiology
Year: 2001
Study type: Clinical Trial
Authors: Halcox JP et al. (5 authors)
DOI: 10.1152/ajpheart.2001.280.6.H2470

What This Study Did, in Plain Language

What Was Tested

This clinical trial paper looks at Bradykinin in the context of hyperparathyroidism.

The identity of endothelium-dependent hyperpolarizing factor (EDHF) in the human circulation remains controversial.

The researchers investigated whether EDHF contributes to endothelium-dependent vasomotion in the forearm microvasculature by studying the effect of K+ and miconazole, an inhibitor of cytochrome P-450, on the response to bradykinin in healthy human subjects.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults.

How the Study Was Run

Study drugs were infused intra-arterially, and forearm blood flow was measured using strain-gauge plethysmography.

What Was Measured

Topics PubMed links to this paper include Aspirin, Biological Factors, Blood Flow Velocity, Brachial Artery, Bradykinin, Cyclooxygenase Inhibitors and Cytochrome P-450 Enzyme Inhibitors.

What This Means in Plain Language

This is a clinical trial of Bradykinin in people with hyperparathyroidism.

The publication is from 2001 (American journal of physiology. Heart and circulatory physiology), a journal based in United States.

More context: the Bradykinin compound page, Hyperparathyroidism research.

Our Notes on the Compound

Bradykinin: A 9-amino-acid peptide that widens blood vessels and causes swelling; given in research studies of blood flow.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.